Gilead Sciences makes a $1.275bn bet on an early-stage oral drug. Can HCXT-2001 challenge injectable IBD therapies?
Gilead Sciences agrees a $1.275 billion deal for HCXT-2001, an oral IL-23R inhibitor. Its IBD potential faces major clinical tests.
Pharma & Biotech
Medical Devices & Diagnostics
Johnson & Johnson advances surgical AI network with Abu Dhabi and Polyphonic platform
Johnson & Johnson advances Polyphonic surgical AI deployment in Abu Dhabi. Clinical validation, data governance and hospital adoption will shape its impact.
Pharma & Biotech
Johnson & Johnson reports long-term ICOTYDE efficacy and safety in plaque psoriasis
Johnson & Johnson reports two-year ICOTYDE psoriasis results, with over 72% achieving PASI 90. See what the data mean for treatment.
Pharma & Biotech
One Carvykti infusion, five years without maintenance: Johnson & Johnson’s tiny trial delivers a striking myeloma signal
Five-year CARTITUDE-2 data show 50% of 20 early-line relapsed multiple myeloma patients remained alive and progression-free after a single Carvykti infusion without maintenance therapy, strengthening the case for using CAR-T before heavily pretreated disease.
Pharma & Biotech
Five-year CARVYKTI data deepen evidence for durable remission in earlier-line multiple myeloma
CARVYKTI keeps half of CARTITUDE-2 patients progression-free and treatment-free at five years after one infusion. See what the data mean.
Pharma & Biotech
Johnson & Johnson’s Tecvayli cuts myeloma progression risk 71% as Europe considers much earlier use
European regulators have backed Tecvayli monotherapy after only one prior multiple myeloma treatment, potentially transforming Johnson & Johnson’s BCMA bispecific from a late-line therapy into a much larger second-line franchise.
Features & Analysis
Johnson & Johnson says RYBREVANT delivered the longest reported survival in EGFR exon 20 lung cancer. Why was p=0.307?
Johnson & Johnson’s final PAPILLON analysis found median overall survival of 34.3 months with first-line RYBREVANT plus chemotherapy versus 27.9 months with chemotherapy, but the protocol-specified comparison was not statistically significant. With 76% of eligible chemotherapy patients later receiving amivantamab, the trial has become a case study in how effective crossover can obscure overall-survival differences.
Medical Devices & Diagnostics
Medtronic’s latest Hugo clearance looks small, but LigaSure could matter enormously in the robotics economics race
FDA clearance for Medtronic’s LigaSure RAS Maryland instrument adds a familiar vessel-sealing technology to Hugo, strengthening the company’s effort to build a broader robotic surgery ecosystem around instruments, procedures and recurring revenue.
Pharma & Biotech
Johnson & Johnson’s Rybrevant reaches 34.3-month survival in EGFR exon 20 lung cancer, but crossover clouds the headline result
Johnson & Johnson’s Rybrevant combination produced a median overall survival of 34.3 months in first-line EGFR exon 20 insertion-positive lung cancer, although the protocol-specified comparison did not reach statistical significance after extensive crossover from chemotherapy.
Pharma & Biotech
What does the PIPE-307 MOONLIGHT-1 miss mean for Contineum Therapeutics stock?
Contineum shares face pressure after Johnson & Johnson’s PIPE-307 misses its Phase 2 depression endpoint, shifting attention to PIPE-791.